Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem-cell transplantation in multiple myeloma.

Jean-Luc Harousseau1, Philippe Moreau, Michel Attal

  • 1Department of Hematology, Hotel Dieu, Nantes, France. jlharousseau@sante.univ-nantes.fr

Best Practice & Research. Clinical Haematology
|July 20, 2005
PubMed
Summary

Autologous stem-cell transplantation (ASCT) is the standard treatment for newly diagnosed multiple myeloma (MM), offering superior outcomes compared to chemotherapy. Double ASCT may benefit patients not achieving a complete response after a single transplant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

Blood cancer journal·2026
Same author

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

Blood·2026
Same author

Toward a cure for multiple myeloma within a decade.

Blood cancer journal·2026
Same author

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Blood advances·2026
Same author

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025.

European journal of haematology·2026
Same author

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Nature medicine·2026

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Multiple myeloma (MM) is a hematologic malignancy where autologous stem-cell transplantation (ASCT) has become standard care.
  • Randomized studies confirm ASCT's superiority over conventional chemotherapy for newly diagnosed MM, particularly in younger patients.

Purpose of the Study:

  • To review the current standards and emerging strategies in autologous stem-cell transplantation for multiple myeloma.
  • To evaluate the efficacy of single versus double ASCT and the role of prognostic markers.

Main Methods:

  • Review of randomized studies and clinical trials, including the IFM94 trial.
  • Analysis of prognostic factors, including biologic markers (beta2-microglobulin, albumin) and genetic markers (hypodiploidy, chromosome 13 deletion).

Related Experiment Videos

Main Results:

  • Autologous stem-cell transplantation (ASCT) with melphalan 200 mg/m2 conditioning and peripheral progenitor cells is the established standard.
  • Double ASCT demonstrates superiority over single ASCT in patients with suboptimal response after the first transplant.
  • Biologic and genetic markers accurately predict prognosis post-ASCT.

Conclusions:

  • ASCT is a cornerstone therapy for newly diagnosed multiple myeloma.
  • Prognostic markers aid in personalizing treatment strategies and predicting outcomes.
  • Allogeneic SCT results remain suboptimal; combined strategies with ASCT are under investigation.